MEDVis model reflects these methodological priorities by integrating evaluation, prescription, and monitoring into a unified platform
When doctors prescribed semaglutide medications like Ozempic, Wegovy, or Rybelsus, patients trusted they were receiving safe, effective treatment that would help them manage their diabetes
Implications for practice This study reassures us that in people with type 2 diabetes at high risk of cardiovascular events due to established CVD or CKD, oral semaglutide offers similar benefits to injectable semaglutide
The SELECT trial, completed in 2023 with over 17,600 participants, showed a 20% reduction in cardiovascular events in patients with established cardiovascular disease and overweight or obesity without diabetes
Post-Treatment Weight Gain While this isnt technically a side effect of the medication itself, one of the top concerns people have is regaining weight once they stop taking semaglutide
Potential improvement in blood pressure and cholesterol levels